Prolonged efficacy and safety of aliskiren vs telmisartan in mild to moderate hypertension after treatment withdrawal

Phase 4, randomised, double-blind trial of aliskiren in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoint: Change in 24-hour mean ambulatory systolic blood pressure over 7-day treatment interruption. Started Feb 2009; status: completed.